Purpose: To investigate whether there is an association between complement factor H (CFH) or LOC387715 genotypes with response to treatment with intravitreal bevacizumab for exudative age-related macular degeneration (AMD).
Design: Retrospective cohort study.
Participants: The study cohort consisted of 86 patients being treated for neovascular AMD with bevacizumab alone.
Methods: Genotype determination for the CFH Y402H and LOC387715 A69S polymorphisms was performed by allele-specific digestion of polymerase chain reaction products. All patients were treated with 1.25 mg intravitreal bevacizumab at 6-week intervals until choroidal neovascularization was no longer active.
Main Outcome Measures: CFH Y402H and LOC387715 A69S polymorphisms. Choroidal neovascular lesion characteristics were ascertained by fluorescein angiography. Snellen visual acuity (VA) was measured before and after treatment.
Results: For the CFH Y402H polymorphism, patients with the CFH TT genotype had the largest choroidal neovascular lesions (P = 0.02). With treatment, VA improved from 20/248 to 20/166 for the CFH TT genotype and from 20/206 to 20/170 for the TC genotype, but fell from 20/206 to 20/341 for the CFH CC genotype (P = 0.016). Only 10.5% of patients with the CFH CC genotype demonstrated improved VA with treatment, compared with 53.7% of CFH TT and TC genotypes (P = 0.004). For the LOC387715 A69S variant, patients with the TT genotype had the largest choroidal neovascular lesions (P = 0.012). There was no significant difference in response to bevacizumab treatment according to LOC387715 genotype.
Conclusions: The AMD-associated CFH Y402H and LOC387715 A69S variants were associated with differences in choroidal neovascular lesion size in this study. Patients with the CFH CC genotype fared significantly worse with intravitreal bevacizumab than did those with the CFH TC and TT genotypes, suggesting a potential pharmacogenetic relationship. Prospective studies to confirm or refute this observation should be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2007.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nutritional Genomics: Implications for Age-Related Macular Degeneration.
Nutrients
November 2024
Ophthalmology Department, Unidade Local de Saúde Coimbra, 3004-561 Coimbra, Portugal.
Age-related macular degeneration (AMD) is a leading cause of vision loss in older individuals, driven by a multifactorial etiology involving genetic, environmental, and dietary factors. Nutritional genomics, which studies gene-nutrient interactions, has emerged as a promising field for AMD prevention and management. Genetic predispositions, such as variants in , , , , and oxidative stress pathways, significantly affect the risk and progression of AMD.
View Article and Find Full Text PDFOmega-3 Fatty Acids as Protective Factors for Age-related Macular Degeneration: Prospective Cohort and Mendelian Randomization Analyses.
Ophthalmology
December 2024
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Centre for Innovation and Precision Eye Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore. Electronic address:
Purpose: Epidemiological studies and clinical trials have reported inconsistent findings regarding the protective role of omega-3 fatty acids in age-related macular degeneration (AMD), we investigated their association in a prospective cohort and examined causality using Mendelian randomization (MR) analyses.
Design: Prospective cohort study and two-sample MR analyses.
Participants: We included individuals of European descent from UK Biobank with plasma omega-3 and docosahexaenoic acid (DHA) measurement.
Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries.
Nat Genet
December 2024
Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.
Article Synopsis
- * By analyzing data from the Million Veteran Program and other cohorts, the study identifies 63 genetic loci linked to AMD, including 30 that were previously unknown, highlighting significant differences in risk among various ancestries.
- * The findings reveal that certain genetic risk factors, like those found in the CFH locus, have varying effects based on ancestry, suggesting that targeted therapies could be developed by considering these genetic differences.
Analysis of Complement Factor H gene polymorphisms and their association with clinical manifestations ofleptospirosis.
Immunogenetics
November 2024
Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, São Paulo, Brazil.
Leptospirosis is caused by pathogenic leptospires, posing a significant public health problem. Host susceptibility to Leptospira infection is a multifactorial trait, and the host's genetic background can influence both the establishment of infection and the severity of the disease. Complement Factor H (FH) plays a crucial role in the interaction between pathogenic bacteria and the host.
View Article and Find Full Text PDFPooled Analysis of the Prognostic Significance of Epidermal Growth Factor Receptor (EGFR) Mutational Status in Combination with Other Driver Genomic Alterations in Stage I Resected Invasive Lung Adenocarcinoma for Recurrence-Free Survival: A Population-Based Study.
Ann Surg Oncol
November 2024
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The prognostic significance of epidermal growth factor receptor (EGFR) mutations in stage I invasive lung adenocarcinoma (LUAD) remains debated. Improving the lung cancer staging system requires further investigation into actionable mutations and their association with survival outcomes.
Patients And Methods: A total of 410 patients with stage I invasive LUAD were analyzed for their driver mutations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!